Ustekinumab in chronic immune-mediated diseases: a review of long term safety and patient improvement

摘要: Ustekinumab is a fully human monoclonal antibody targeting the common p40 subunit shared by interleukin (IL)-12 and IL-23. prevents interaction of IL-12 IL-23 with their cell surface receptors, thus blocks T helper (Th)-1 Th-17 inflammatory pathways. has been evaluated in treatment various chronic immune-mediated diseases including, psoriasis, psoriatic arthritis, Crohn’s disease, multiple sclerosis. It led to rapid durable improvement psoriasis area severity index patients moderate severe psoriasis. also improved joint symptoms arthritis. Results disease were more mitigated, albeit symptomatic refractory tumor necrosis factor-α inhibitors. did not reduce number magnetic resonance imaging brain lesions The most adverse events have observed during clinical trials are mild intensity, include respiratory tract infections, nasopharyngitis, headaches, injection site reactions. A pooled analysis trial data indicated no specific patterns infection or malignancy under long-term ustekinumab administration. easy use, comfortable therapeutic regimen, improves quality life patients, appears be an attractive biological that adapted accepted